Li Ke, Yao Wenqi, Zheng Xiudan, Liao Kan
State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China.
Cell Res. 2009 Aug;19(8):1006-17. doi: 10.1038/cr.2009.76.
Berberine is identified to lower the serum cholesterol level in human and hamster through the induction of low density lipoproteins (LDL) receptor in hepatic cells. To evaluate its potential in preventing atherosclerosis, the effect of berberine on atherosclerosis development in apolipoprotein E-deficient (apoE(-/-)) mice was investigated. In apoE(-/-) mice, berberine induced in vivo foam cell formation and promoted atherosclerosis development. The foam cell formation induced by berberine was also observed in mouse RAW264.7 cells, as well as in mouse and human primary macrophages. By inducing scavenger receptor A (SR-A) expression in macrophages, berberine increased the uptake of modified LDL (DiO-Ac-LDL). Berberine-induced SR-A expression was also observed in macrophage foam cells in vivo and in the cells at atherosclerotic lesion. Analysis in RAW264.7 cells indicated that berberine induced SR-A expression by suppressing PTEN expression, which led to sustained Akt activation. Our results suggest that to evaluate the potential of a cholesterol-reducing compound in alleviating atherosclerosis, its effect on the cells involved in atherosclerosis development, such as macrophages, should also be considered. Promotion of foam cell formation could counter-balance the beneficial effect of lowering serum cholesterol.
小檗碱可通过诱导肝细胞中低密度脂蛋白(LDL)受体来降低人和仓鼠的血清胆固醇水平。为评估其预防动脉粥样硬化的潜力,研究了小檗碱对载脂蛋白E缺陷(apoE(-/-))小鼠动脉粥样硬化发展的影响。在apoE(-/-)小鼠中,小檗碱诱导体内泡沫细胞形成并促进动脉粥样硬化发展。在小鼠RAW264.7细胞以及小鼠和人类原代巨噬细胞中也观察到小檗碱诱导的泡沫细胞形成。通过诱导巨噬细胞中清道夫受体A(SR-A)的表达,小檗碱增加了对修饰LDL(DiO-Ac-LDL)的摄取。在体内巨噬细胞泡沫细胞和动脉粥样硬化病变处的细胞中也观察到小檗碱诱导的SR-A表达。对RAW264.7细胞的分析表明,小檗碱通过抑制PTEN表达诱导SR-A表达,这导致Akt持续激活。我们的结果表明,要评估一种降胆固醇化合物在减轻动脉粥样硬化方面的潜力,还应考虑其对参与动脉粥样硬化发展的细胞(如巨噬细胞)的影响。促进泡沫细胞形成可能会抵消降低血清胆固醇的有益作用。
Arterioscler Thromb Vasc Biol. 2006-5
Proc Natl Acad Sci U S A. 2024-4-9
Pharmaceuticals (Basel). 2023-12-20
Adv Sci (Weinh). 2023-12
Exp Ther Med. 2022-7-19
Evid Based Complement Alternat Med. 2021-12-31
Front Pharmacol. 2021-11-26